Companies
Neoplants
Neo P1 — VOC-metabolizing houseplant.
- Country
- France
Coverage
| CN | EU | US | |
|---|---|---|---|
| crop-biotech | ✓ | ✓ | ✓ |
Regulatorsusda-aphisepaefsamoa-china
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $20M in total funding | agfundernews.com · techcrunch.com · businesswire.com · forbes.com |
| Capacity | 200 prototypes produced as of 2024 | neoplants.vn |
| Regulatory approval | USDA approval for Neo P1 is ongoing | agfundernews.com · neoplants.com · neoplants.vn |
| Revenue | pre-revenue status reported as of October 2022 medium confidence | infonet.fr · prospeo.io · forbes.com |
| Production site | partner growing facilities in the United States; research lab in Saint-Ouen-Sur-Seine, France | businesswire.com · forbes.com |
Independent sources: agfundernews.com · businesswire.com · forbes.com · infonet.fr · prospeo.io · techcrunch.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Genetic design of ornamental & landscape plants | crop-biotech | No data | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.